Table 1.
Characteristics of patients treated with SGN-CD33A by genotype
| CC (n=10) | CT/TT (n=10) | Total (n=20) | p value | |
|---|---|---|---|---|
| Gender | 0.361 | |||
| Female | 5 (50.0%) | 7 (70.0%) | 12 (60.0%) | |
| Male | 5 (50.0%) | 3 (30.0%) | 8 (40.0%) | |
| Age | 0.418 | |||
| Mean (range) | 67.3 (27.5-80.0) | 72.3 (42.0 -82.6) | 69.8 (27.5-82.6) | |
| ECOG | 0.160 | |||
| 0 | 2 (20.0%) | 5 (50.0%) | 7 (35.0%) | |
| 1 | 8 (80.0%) | 5 (50.0%) | 13 (65.0%) | |
| Risk group | 0.148 | |||
| Adverse | 7 (70.0%) | 4 (40.0%) | 11 (55.0%) | |
| Favorable | 1 (10.0%) | 0 (0.0%) | 1 (5.0%) | |
| Intermed. | 2 (20.0%) | 6 (60.0%) | 8 (40.0%) | |
| BM blast % | 0.334 | |||
| Median (Q1, Q3) | 64.0 (43.2, 80.0) | 54.0 (24.0,66.0) | 56.0 (36.0,78.0) | |
| WBC | 0.200 | |||
| Mean (SD) | 13.6 (17.1) | 5.6 (8.1) | 9.6 (13.7) | |
| Median (Q1, Q3) | 5.3 (1.7, 16.5) | 1.7 (1.2, 3.8) | 2.5 (1.5, 16.4) | |
| Range | 0.8 - 51.7 | 0.4 - 23.1 | 0.4 - 51.7 | |
| IQR | 14.8 | 2.7 | 14.9 | |
| Platelets | 0.913 | |||
| Mean (SD) | 50.3 (41.2) | 52.4 (43.9) | 51.4 (41.5) | |
| Median (Q1, Q3) | 34.0 (22.0, 75.0) | 32.0 (21.8,90.8) | 34.0 (19.8,89.5) | |
| Range | 11.0 - 133.0 | 5.0 - 116.0 | 5.0 - 133.0 | |
| IQR | 53.0 | 69.0 | 69.8 | |
| De novo | 0.531 | |||
| Yes | 1 (10.0%) | 2 (20.0%) | 3 (15.0%) | |
| No | 9 (90.0%) | 8 (80.0%) | 17 (85.0%) | |
| Line of tx | 0.361 | |||
| 1st | 3 (30.0%) | 5 (50.0%) | 8 (40.0%) | |
| 2nd | 7 (70.0%) | 5 (50.0%) | 12 (60.0%) |
BM bone marrow, ECOG Eastern Cooperative Oncology Group, IQR interquartile range, tx treatment, WBC white blood cell